Table 2: Overall survival and values of nivolumab.

Nivo in 2nd-line OS gains in days/grade (OS/gr) & HR $C/LYG Relative values (RV) (100,000/LYG)
Nivo vs. Doc, squamous-NSCLC [4] 96/B & 0.59
P = 0.00025
$488,524 0.20
Nivo vs. Doc, non-squamous- NSCLC, CheckMate 057 [5] 84/C & 0.73
P = 0.0016
$558,326 0.18
Subset analysis in >10% positive PD-L1 264/A
& 0.27
$177,645 0.56

Nivo, Atezo and Pembro demonstrated AEs gr ¾ of < 20%, maintained and/or improved the QoL and carried no black box warnings. The $C/LYG were weighed vs. $100,000, the acceptable Average Cost Effectiveness Ratio (ACER) in the US. Relative Values (RV) were computed as $100,000/C/LYG.